ProQR Therapeutics Q1 revenue falls and misses estimates

ProQR Therapeutics NV

12/05/2026 12:09

Overview

RNA therapeutics developer's Q1 revenue fell and missed analyst expectations

Q1 net loss widened to €13.4 mln from €10.1 mln a year earlier

Company ended Q1 with €81.1 mln cash, guiding runway into mid-2027

Outlook

ProQR expects AX-0810 target engagement data in healthy volunteers in Q2 2026

Company targets initial clinical data from biliary atresia trial in China in H1 2027

Result Drivers

R&D INVESTMENT - Co said continued investment in research and development drove operating costs, including pipeline expansion and advancement of clinical programs

PIPELINE ADVANCEMENT - Co highlighted progress in its Axiomer platform, AI-enabled discovery, and partnerships as key operational focuses during the quarter

Company press release: ID:nGNEn0HVK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
EUR 2.03 mln
EUR 5.25 mln (6 Analysts)
Q1 EPS
-EUR 0.13
Q1 Net Income
-EUR 13.38 mln
Q1 Basic EPS
-EUR 0.13
Q1 Operating Income
-EUR 13.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.50, about 490.1% above its May 11 closing price of $1.61

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)